

Registered Number 905237

Nurofen Limited
Annual Report and Financial statements
for the year ended 31 December 2014

WEDNESDAY



L4H18GJC

LD3

30/09/2015

#336

COMPANIES HOUSE

Nurofen Limited

Directors' report for the year ended 31 December 2014

The directors present their report and the unaudited financial statements of the Company for the year ended 31 December 2014.

Principal activities

Nurofen Limited is a dormant Company.

The Company has not traded in either the current year or prior years and consequently has made neither a profit nor a loss.

Directors

The directors who held office during the year and up to the date of signing this report are shown below:

W R Mordan
C J Davies
P N Clements

Directors' indemnity

On 28 July 2009 Reckitt Benckiser Group plc executed a deed poll of indemnity for the benefit of each individual who is at any time on, or after 28 July 2009, an officer of Reckitt Benckiser Group plc and/or any company within the Reckitt Benckiser group of companies in respect of costs defending claims against them and third party liabilities.

Statement of directors' responsibilities

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006.

Nurofen Limited

They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

By order of the Board



C A Logan
Secretary

30/9/2015

Nurofen Limited

Balance sheet as at 31 December 2014

	Notes	31 December 2014 £	31 December 2013 £
Current assets			
Debtors	1	399,865	399,865
Net assets		399,865	399,865
Capital and reserves			
Called up share capital	2	100	100
Profit and loss account	3	399,765	399,765
Total shareholder's funds		399,865	399,865

For the financial year ended 31 December 2014 the Company was entitled to exemption from audit under section 480 of the Companies Act 2006 (the "Act").

The members have not required the Company to obtain an audit of its accounts for the period in question in accordance with section 476 of the Act.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of accounts.

The financial statements on pages 3 to 5 were approved by the board of directors on and were signed on its behalf by:



30/09/15

C J Davies
Director

Nurofen Limited
Registered number 905237

Nurofen Limited

Accounting policies

These financial statements are prepared on the going concern basis, under the historical cost convention and in accordance with the Companies Act 2006 and applicable accounting standards. The principal accounting policies are set out below.

Cash flow statement and related party disclosures

The Company is a wholly owned subsidiary of Reckitt Benckiser Group plc and is included in the consolidated financial statements of Reckitt Benckiser Group plc, which are publicly available. Consequently the Company has taken advantage of the exemption from preparing a cash flow statement under the terms of Financial Reporting Standard No 1 ("FRS 1"). The Company is also exempt under the terms of Financial Reporting Standard No 8 ("FRS 8") from disclosing related party transactions with entities that are part of the Reckitt Benckiser Group plc group.

Nurofen Limited

Notes to the financial statements for the year ended 31 December 2014

1 Debtors

	31 December 2014 £	31 December 2013 £
Falling due within one year:		
Amounts owed by group undertakings	399,865	399,865

Amounts owed by group undertakings are unsecured, interest free and are repayable on demand.

2 Called up share capital

	31 December 2014 £	31 December 2013 £
Allotted, called up and fully paid		
100 ordinary shares of £1 each	100	100

3 Reserves

	Profit and loss account £
At 1 January 2014 and at 31 December 2014	399,765

4 Ultimate holding company

The immediate parent undertaking is RB Holdings (Nottingham) Limited, a company registered in England and Wales.

The ultimate parent undertaking and controlling party is Reckitt Benckiser Group plc, a company registered in England and Wales. Copies of the group accounts of Reckitt Benckiser Group plc can be obtained from 103-105 Bath Road, Slough, Berkshire, SL1 3UH.